Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis
Table 1
Main characteristics of the studies included in the meta-analysis.
Study
Interventions
Tumor
Line
Patients, no. (%)
Male
<65
Smoker
EGFR wild type
KRAS wild type
No liver metastasis
Bellmunt J 2017
Pembrolizumab vs. ICC
Urothelial carcinoma
>1
402 (74)
230 (42)
—
230 (42)
351 (65)
—
—
355 (66)
Borghaei H 2015
Nivolumab vs. docetaxel
NS-NSCLC
>1
319 (55)
339 (58)
402 (69)
—
458 (79)
340 (81)
123 (66)
—
Brahmer J 2015
Nivolumab vs. docetaxel
S-NSCLC
>1
208 (76)
152 (56)
206 (76)
119 (53)
—
—
—
—
Carbone DP 2017
Nivolumab vs. ICC
NSCLC
1
332 (61)
281 (52)
362 (67)
—
475 (89)
—
—
—
Fehrenbacher L 2016
Atezolizumab vs. docetaxel
NSCLC
>1
169 (59)
174 (61)
193 (67)
195 (68)
231 (80)
147 (89)
45 (62)
—
Ferris RL 2016
Nivolumab vs. standard therapy
HNSCC
>1
300 (83)
248 (69)
287 (80)
149 (57)
—
—
—
—
Herbst RS 2016
Pembrolizumab vs. docetaxel
NSCLC
>1
634 (61)
604 (58)
689 (66)
—
—
875 (91)
—
—
Kang YK 2016
Nivolumab vs. placebo
Gastric or GOJ cancer
>1
348 (71)
284 (58)
350 (71)
—
—
—
—
387 (78)
Motzer RJ 2015
Nivolumab vs. everolimus
RCC
>1
619 (75)
497 (61)
—
—
—
—
—
—
Powles T 2018
Atezolizumab vs. chemotherapy
Urothelial carcinoma
>1
—
—
506 (54)
—
666 (72)
—
—
793 (85)
Rittmeyer A 2016
Atezolizumab vs. docetaxel
NSCLC
>1
520 (61)
453 (53)
535 (63)
463 (54)
694 (82)
628 (88)
203 (24)
—
Robert C 2015
Nivolumab vs. dacarbazine
Melanoma
1
246 (59)
200 (48)
148 (35)
—
—
—
—
—
Shitara K 2018
Pembrolizumab vs. paclitaxel
Gastric or GOJ cancer
>1
286 (72)
232 (59)
214 (54)
—
—
—
—
—
Antonia SJ 2018
Durvalumab+chemoradiotherapy vs. chemoradiotherapy
NSCLC
>1
500 (70)
391 (55)
362 (51)
303 (67)
649 (91)
—
—
—
Gandhi L 2018
Pembrolizumab+platinum vs. platinum
NS-NSCLC
1
363 (59)
312 (51)
347 (57)
388 (67)
543 (88)
—
—
—
Horn L 2018
Atezolizumab+carboplatin and etoposide vs. carboplatin and etoposide
SCLC
1
261 (65)
217 (54)
263 (65)
—
—
—
—
254 (63)
Motzer RJ 2018
Nivolumab+ipilimumab vs. sunitinib
RCC
1
615 (73)
524 (62)
—
214 (28)
—
—
—
670 (79)
Paz-Ares L 2018
Pembrolizumab+ICC vs. ICC
S-NSCLC
1
455 (81)
254 (45)
396 (71)
353 (63)
—
—
—
—
ICC: investigator’s choice chemotherapy; NSCLC: non-small-cell lung cancer; NS-NSCLC: nonsquamous non-small-cell lung cancer; S-NSCLC: squamous non-small-cell lung cancer; HNSCC: squamous-cell carcinoma of the head and neck; GOJ: gastrooesophageal junction; RCC: renal cell carcinoma.
